Investigational dry eye treatment moves to next phase


Alacrity Biosciences has announced positive results from a Phase II study of its treatment for dry eye, ALTY-0501.

Alacrity Biosciences has announced positive results from a Phase II study of its treatment for dry eye, ALTY-0501.

ALTY-0501 is a proprietary topical formulation of 0.025% doxycycline in a non-antimicrobial dose, which acts to inhibit matrix metalloproteinase-9 (MMP-9). By inhibiting MMP-9, ALTY-0501 is thought to prevent the disruption of the epithelial barrier on the ocular surface.

The Phase II double-masked, randomized, parallel-group study enrolled 160 subjects to assess the safety and efficacy of the drug. Patients with dry eye were exposed to a controlled adverse environment on day one and asked to self-administer ALTY-0501 eye drops or vehicle eye drops four times a day. Patients were re-exposed to the controlled adverse environment on days 28 and 56. Environmental damage was assessed using fluorescein staining and symptoms were measured daily through patient diaries throughout the study period.

Patients who received ALTY-0501 demonstrated statistically significantly lower scores after fluorescein staining, following exposure, than the control group on day 28 (p<0.05). The drug also demonstrated statistically significant advantages compared with vehicle in the patient diary scores. Specifically, patient diary scores reflected statistically significantly lower scores for the symptoms of burning (p<0.0001), stinging (p<0.0001) and grittiness (p<0.0001) in the active treatment group.

Alacrity plans to initiate Phase III trials early in 2008.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.